Crinetics Pharmaceuticals, Inc

(NASDAQ:CRNX)

Latest On Crinetics Pharmaceuticals, Inc (CRNX):

Date/Time Type Description Signal Details
2023-05-25 19:43 ESTNewsCrinetics Pharmaceuticals And Its Value Proposition In AcromegalyN/A
2023-05-04 23:54 ESTNewsCrinetics Pharmaceuticals GAAP EPS of -$0.85 misses by $0.01, revenue of $2.67M beats by $2.43MN/A
2023-03-06 12:48 ESTNewsEvaluating Crinetics' Oral Long Shot For AcromegalyN/A
2023-02-28 18:44 ESTNewsCrinetics Pharmaceuticals GAAP EPS of -$0.84 misses by $0.01, revenue of $0.71M beats by $0.41MN/A
2022-12-30 22:15 ESTNewsCrinetics: FY23 Could Be Turning Point With Two Phase 3 Acromegaly ReadoutsN/A
2022-11-29 04:07 ESTNewsCrinetics says FDA didn’t clear Phase 2 study request for hyperinsulinism drugN/A
2022-11-15 00:39 ESTNewsCrinetics Pharmaceuticals GAAP EPS of -$0.78 beats by $0.03, revenue of $0.46M beats by $0.26MN/A
2022-08-12 17:31 ESTNewsCrinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28MN/A
2022-06-13 22:31 ESTNewsCrinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection PointN/A
2022-05-25 15:30 ESTNewsCrinetics hormone CRN04894 therapy shows promise in early-stage studyN/A
2022-05-13 09:56 ESTNewsCrinetics Pharmaceuticals GAAP EPS of -$0.73 misses by $0.17, revenue of $3.13M misses by $2.07MN/A
2022-04-29 23:10 ESTNewsCrinetics: An Orphan Disease Innovator On The RiseN/A
2022-04-24 11:40 ESTNewsCrinetics Pharmaceuticals: Endocrinology Focus To Pay Off As Multi-Faceted Pipeline Makes ProgressN/A
2022-04-13 16:17 ESTNewsCrinetics Pharmaceuticals prices $125M stock offeringN/A
2022-04-01 04:52 ESTNewsCrinetics stock gains on hyperinsulinism candidate's trial data; JMP raises PTN/A
2022-03-31 09:08 ESTNewsCrinetics Pharmaceuticals reports resultsN/A
2022-03-30 16:39 ESTNewsCrinetics shows dose-dependent effect of hyperinsulinism candidate in early trialN/A
2022-03-18 16:25 ESTNewsCrinetics delays early Phase 1 data for experimental therapy due to COVID-19N/A
2022-02-28 09:07 ESTNewsCrinetics, Sanwa ink licensing deal for cancer/hormonal disorder drug in JapanN/A
2021-10-22 05:14 ESTNewsCrinetics Pharmaceuticals prices $150M in stock offeringN/A
2021-10-21 03:29 ESTNewsCrinetics drops after announcing common stock offeringN/A
2021-09-21 15:29 ESTNewsCrinetics posts preliminary results from early-stage CRN04777 hyperinsulinism studyN/A
2021-09-21 15:23 ESTNewsCrinetics Pharmaceuticals (CRNX) Investor Presentation - SlideshowN/A
2021-09-02 17:30 ESTNewsCrinetics Pharmaceuticals names Jeff Knight as chief operating officerN/A
2021-08-10 23:06 ESTNewsCrinetics Pharmaceuticals posts positive data from early-stage CRN04894 trialN/A
2021-08-10 23:05 ESTNewsCrinetics Pharmaceuticals EPS misses by $0.10N/A
2021-07-29 16:43 ESTNewsCrinetics Pharmaceuticals proposes $15M in private placement with Frazier HealthcareN/A
2021-07-21 02:52 ESTNewsCrinetics doses first patient in late-stage oral paltusotine acromegaly trialN/A
2021-05-07 06:27 ESTNewsCrinetics Pharmaceuticals EPS misses by $0.04N/A
2021-04-08 07:33 ESTNewsCrinetics Pharma raises $75M via equity offeringN/A
2021-03-30 23:41 ESTNewsCrinetics Pharmaceuticals, Inc. (CRNX) CEO Scott Struthers on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-30 23:41 ESTNewsCrinetics Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call PresentationN/A
2021-01-23 04:21 ESTNewsCrinetics Pharmaceuticals (CRNX) Presents At 39th Annual J.P. Morgan Healthcare Conference - SlideshowN/A
2020-12-13 03:42 ESTFinancialsCompany financials have been released.Neutral
2020-11-24 07:37 ESTAnalyst RatingThe Analyst Target Price has increased from $32.8 to $33.6.Buy
2020-11-09 11:40 ESTFinancialsCompany financials have been released.Neutral
2020-11-09 11:40 ESTEarnings EstimateAn EPS average of -$0.59 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-07 15:30 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 06:16 ESTNewsCrinetics Pharmaceuticals EPS misses by $0.03N/A
2020-10-30 12:37 ESTAnalyst RatingThe Analyst Target Price has decreased from $36.75 to $32.8.Neutral
2020-10-26 14:41 ESTNewsCrinetics Pharma lead drug successful in mid-stage acromegaly studyN/A
2020-09-26 12:27 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 04:35 ESTFinancialsCompany financials have been released.Neutral
2020-09-08 04:25 ESTAnalyst RatingThe Analyst Target Price has decreased from $36.8 to $36.75.Neutral
2020-09-05 01:11 ESTNewsCrinetics Pharma to advance ACTH antagonist candidate into the clinicN/A
2020-09-05 00:31 ESTFinancialsCompany financials have been released.Neutral
2020-09-02 11:29 ESTNewsCrinetics Pharmaceuticals- Superior Molecules In EndocrinologyN/A
2020-08-09 08:28 ESTFinancialsCompany financials have been released.Neutral
2020-08-07 16:03 ESTNewsCrinetics Pharmaceuticals EPS beats by $0.02N/A
2020-07-31 00:39 ESTFinancialsCompany financials have been released.Neutral

About Crinetics Pharmaceuticals, Inc (CRNX):

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly and neuroendocrine tumors. The company is also developing CRN01941, an oral selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; an oral selective nonpeptide somatostatin type 5 receptor agonist for treating congenital hyperinsulinism; and an oral adrenocorticotrophic hormone antagonist for the treatment of cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

CRNX Quotes by TradingView

See Advanced Chart

General

  • Name Crinetics Pharmaceuticals, Inc
  • Symbol CRNX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 68
  • Fiscal Year EndDecember
  • IPO Date2018-07-18
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.crinetics.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 1102.47
  • Price/Book (Most Recent Quarter) 2.99
  • Enterprise Value Revenue 961.96
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.55
  • Operating Margin -17443%
  • Return on Assets -25%
  • Return on Equity -42%
  • Revenue 392000
  • Earnings Per Share -$1.62
  • Revenue Per Share $0.01
  • Gross Profit -40313000
  • Quarterly Earnings Growth -80.7%
View More

Highlights

  • Market Capitalization 531.37 million
  • EBITDA -40113000
  • PE Ratio -16.43
  • Analyst Target Price $33.6
  • Book Value Per Share $5.69
View More

Share Statistics

  • Shares Outstanding 32.92 million
  • Shares Float 20.69 million
  • % Held by Insiders 450%
  • % Held by Institutions 95.14%
  • Shares Short 1.53 million
  • Shares Short Prior Month 1.38 million
  • Short Ratio 13.29
  • Short % of Float 6%
  • Short % of Shares Outstanding 5%
View More

Technicals

  • Beta 1.23
  • 52 Week High $23.7
  • 52 Week Low $11.61
  • 50 Day Moving Average 15.77
  • 200 Day Moving Average 14.69
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Crinetics Pharmaceuticals, Inc (CRNX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Crinetics Pharmaceuticals, Inc (CRNX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-06$N/A-$0.56-$0.53-6.38%
2020-06-302020-08-07$N/A-$0.53-$0.554.21%
2020-03-312020-05-08$N/A-$0.71-$0.63-12.66%
2019-12-312020-03-09$321000-$0.60-$0.6811.35%
2019-09-302019-11-12$505000-$0.60-$0.54-11.92%
2019-06-302019-08-13$N/A-$0.51-$0.46-11.79%
2019-03-312019-05-13$367000-$0.37-$0.394.61%
2018-12-312019-03-13$781000-$0.35-$0.4115.09%
2018-09-302018-11-13$548000-$0.38-$0.34-10.47%
2018-06-302018-08-30$657000-$0.33-$0.31-7.32%

Crinetics Pharmaceuticals, Inc (CRNX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development N/A N/A N/A N/A 11.82 million
Income Before Tax N/A N/A N/A -14.55 million -14.43 million
Selling General Administrative N/A N/A N/A 3.39 million 3.91 million
Gross Profit N/A N/A N/A -11.82 million 505000
Ebit N/A N/A N/A -15.21 million -15.23 million
Operating Income N/A N/A N/A -15.21 million -15.23 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A 321000 505000
Cost of Revenue N/A N/A N/A 12.14 million N/A
Total Other Income Expense Net N/A N/A N/A 665000 799000
Net Income From Continuing Operations N/A N/A N/A -14.55 million -14.43 million
Net Income Applicable to Common Shares -18.32 million -16.49 million -17.36 million -14.55 million -14.43 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A -12.8 million 20.45 million
Change to Liabilities -752000 -831000 2.39 million 674000 114000
Total Cash Flow from Investing Activities -24.83 million 17.6 million 16.34 million -12.82 million 20.45 million
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A N/A 17000 22000
Change to Operating Activities -2.04 million -1.25 million 491000 -1.47 million -1.11 million
Change in Cash N/A N/A N/A -26.25 million 6.86 million
Total Cash from Operating Activities -18 million -15.86 million -12.23 million -13.45 million -13.61 million
Depreciation N/A N/A N/A 229000 228000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income 2.86 million 2.48 million 2.01 million 1.66 million 1.59 million
Capital Expenditures N/A N/A N/A 28000 N/A
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities N/A N/A N/A 13.24 million 12.99 million
Total Stockholder Equity N/A N/A N/A 117.14 million 129.52 million
Other Current Liabilities 810000 N/A N/A N/A N/A
Total Assets N/A N/A N/A 130.38 million 142.51 million
Common Stock 333.15 million 330.3 million 219.43 million 210.79 million 208.58 million
Other Current Assets N/A N/A N/A 2.48 million N/A
Retained Earnings -145.97 million -127.65 million -111.16 million -93.8 million -79.25 million
Other Liabilities 28000 34000 39000 49000 60000
Other Assets 500000 500000 500000 582000 500000
Cash N/A N/A N/A 40.33 million 66.58 million
Total Current Liabilities 8.83 million N/A N/A 8.34 million 7.88 million
Other Stockholder Equity 44000 127000 167000 148000 198000
Property, Plant & Equipment 5.7 million 6.01 million 6.22 million 6.46 million 6.61 million
Total Current Assets 194.12 million N/A N/A 123.34 million 135.4 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 187.22 million 202.77 million 108.44 million 117.14 million 129.52 million
Short Term Investments N/A N/A N/A 78.07 million 65.09 million
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 4.69 million N/A N/A 2.7 million 2.11 million

Crinetics Pharmaceuticals, Inc (CRNX) Chart:

Crinetics Pharmaceuticals, Inc (CRNX) News:

Below you will find a list of latest news for Crinetics Pharmaceuticals, Inc (CRNX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Crinetics Pharmaceuticals, Inc (CRNX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-12-20250CALL0 091.98TRUE00
2024-12-203023.3CALL0 171.73TRUE00
2024-12-20350CALL0 062.13TRUE00
2024-12-20360CALL0 058.28TRUE00
2024-12-20370CALL0 060.32TRUE00
2024-12-20380CALL0 057.75TRUE00
2024-12-20390CALL0 053.95TRUE00
2024-12-204011.1CALL0 1660.57TRUE00
2024-12-20410CALL0 057.44TRUE00
2024-12-20420CALL0 054.29TRUE00
2024-12-20430CALL0 052.72TRUE00
2024-12-20440CALL0 053.16TRUE00
2024-12-20458.5CALL0 1051.76TRUE00
2024-12-20460CALL0 052.05TRUE00
2024-12-204710.4CALL0 551.31TRUE00
2024-12-20484.5CALL0 150.26TRUE00
2024-12-20490CALL0 049.47TRUE00
2024-12-20505CALL0 1249.45TRUE00
2024-12-20553CALL0 1346.83FALSE00
2024-12-20602.8CALL0 2154.96FALSE00
2024-12-20650.44CALL0 1365.8FALSE00
2024-12-20701.35CALL0 210FALSE00
2024-12-20750.9CALL0 100FALSE00
2024-12-20801.15CALL0 30FALSE00
2024-12-20250.75PUT0 80FALSE00
2024-12-20300.95PUT0 110FALSE00
2024-12-20351PUT0 7107.39FALSE00
2024-12-20360.85PUT0 7102.28FALSE00
2024-12-20370.95PUT0 598.96FALSE00
2024-12-20381.35PUT0 130FALSE00
2024-12-20391.15PUT0 40FALSE00
2024-12-20401.1PUT0 20FALSE00
2024-12-20411.3PUT10 259.19FALSE1.30
2024-12-20421.8PUT0 160.17FALSE00
2024-12-20431.95PUT0 170.53FALSE00
2024-12-20440PUT0 066.67FALSE00
2024-12-20454PUT0 1063.44FALSE00
2024-12-20462.56PUT0 159.51FALSE00
2024-12-20470PUT0 054.64FALSE00
2024-12-20489.9PUT0 053.82FALSE00
2024-12-20490PUT0 054.65FALSE00
2024-12-20504.6PUT0 654.55FALSE00
2024-12-20550PUT0 053.99TRUE00
2024-12-20600PUT0 050.07TRUE00
2024-12-20650PUT0 051.46TRUE00
2024-12-20700PUT0 052.74TRUE00
2024-12-20750PUT0 054.63TRUE00
2024-12-20800PUT0 068.84TRUE00
2025-01-172529.88CALL0 074.55TRUE00
2025-01-173025.14CALL0 057.08TRUE00
2025-01-17350CALL0 058.95TRUE00
2025-01-17400CALL0 051.34TRUE00
2025-01-174510.25CALL0 350.98TRUE00
2025-01-17507.1CALL0 1751.16TRUE00
2025-01-17553.84CALL3 57042.77FALSE-0.16-0.04
2025-01-17602CALL0 220FALSE00
2025-01-17651.45CALL0 60FALSE00
2025-01-17700.85CALL0 320FALSE00
2025-01-17751.3CALL0 130FALSE00
2025-01-17801CALL0 590FALSE00
2025-01-17250.55PUT0 40FALSE00
2025-01-17300.6PUT0 30FALSE00
2025-01-17351.85PUT0 00FALSE00
2025-01-17401.65PUT0 200FALSE00
2025-01-17450PUT0 055.63FALSE00
2025-01-17504PUT0 1552.42FALSE00
2025-01-17550PUT0 045.42TRUE00
2025-01-17600PUT0 043.03TRUE00
2025-01-17650PUT0 043.57TRUE00
2025-01-17700PUT0 047.77TRUE00
2025-01-17750PUT0 054.38TRUE00
2025-01-17800PUT0 061.13TRUE00
2025-03-21300CALL0 054.04TRUE00
2025-03-213520.45CALL0 355.11TRUE00
2025-03-21400CALL0 052.37TRUE00
2025-03-21450CALL0 050.44TRUE00
2025-03-21500CALL0 048.47TRUE00
2025-03-21557.9CALL0 455.47FALSE00
2025-03-21603.3CALL0 151.45FALSE00
2025-03-21652.7CALL0 845.84FALSE00
2025-03-21700CALL0 052.4FALSE00
2025-03-21752.1CALL0 1155.64FALSE00
2025-03-21801.5CALL0 163.25FALSE00
2025-03-21300.38PUT0 50FALSE00
2025-03-21351.4PUT0 1074.69FALSE00
2025-03-21400PUT0 060.32FALSE00
2025-03-21450PUT0 052.17FALSE00
2025-03-21500PUT0 055.34FALSE00
2025-03-21550PUT0 053.17TRUE00
2025-03-21600PUT0 047.48TRUE00
2025-03-21650PUT0 046.53TRUE00
2025-03-21700PUT0 045.93TRUE00
2025-03-21750PUT0 042.07TRUE00
2025-03-21800PUT0 050.4TRUE00
2025-12-192525.75CALL0 1061.33TRUE00
2025-12-19300CALL0 057.3TRUE00
2025-12-19350CALL0 055.81TRUE00
2025-12-19400CALL0 052.42TRUE00
2025-12-19450CALL0 050.56TRUE00
2025-12-195014.18CALL0 5049.7TRUE00
2025-12-19559CALL0 248.54FALSE00
2025-12-196011CALL0 648.31FALSE00
2025-12-19650CALL0 045.81FALSE00
2025-12-19705.1CALL0 046.66FALSE00
2025-12-19758CALL0 144.26FALSE00
2025-12-19800CALL0 045.75FALSE00
2025-12-19250PUT0 00FALSE00
2025-12-19300PUT0 060.31FALSE00
2025-12-19350PUT0 052.3FALSE00
2025-12-19400PUT0 050.42FALSE00
2025-12-19450PUT0 049.78FALSE00
2025-12-195012.75PUT0 1047.36FALSE00
2025-12-19550PUT0 048.05TRUE00
2025-12-19600PUT0 047.19TRUE00
2025-12-19650PUT0 046.1TRUE00
2025-12-197026.9PUT0 144.78TRUE00
2025-12-19750PUT0 044.61TRUE00
2025-12-19800PUT0 043.05TRUE00
2026-01-162530.2CALL0 158.75TRUE00
2026-01-16300CALL0 054.97TRUE00
2026-01-16350CALL0 055.45TRUE00
2026-01-164019.36CALL0 1053.41TRUE00
2026-01-16450CALL0 051.27TRUE00
2026-01-165012.5CALL0 250.24TRUE00
2026-01-165514.2CALL0 150.11FALSE00
2026-01-16600CALL0 048.75FALSE00
2026-01-16650CALL0 048.47FALSE00
2026-01-16704CALL0 547.23FALSE00
2026-01-16750CALL0 045.04FALSE00
2026-01-16802.63CALL0 545.4FALSE00
2026-01-16250PUT0 00FALSE00
2026-01-16300PUT0 00FALSE00
2026-01-16350PUT0 054.17FALSE00
2026-01-16400PUT0 052.08FALSE00
2026-01-16450PUT0 051.08FALSE00
2026-01-16500PUT0 048.52FALSE00
2026-01-16550PUT0 046.92TRUE00
2026-01-16600PUT0 046.12TRUE00
2026-01-16650PUT0 046.42TRUE00
2026-01-16700PUT0 045.48TRUE00
2026-01-16750PUT0 045.01TRUE00
2026-01-16800PUT0 043.8TRUE00

Latest CRNX Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST5$17.17
Jun 13, 2022 7:59 PM EST100$17.19
Jun 13, 2022 7:59 PM EST1$17.17
Jun 13, 2022 7:59 PM EST100$17.2
Jun 13, 2022 7:59 PM EST100$17.2

Crinetics Pharmaceuticals, Inc (CRNX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120038179/0001209191-20-038179-index.htm
2018-07-10UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1658247/000000000018021079/0000000000-18-021079-index.htm
2019-08-16UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1658247/000000000019012560/0000000000-19-012560-index.htm
2018-09-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000031506618002299/0000315066-18-002299-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000031506619000968/0000315066-19-000968-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000031506620000861/0000315066-20-000861-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019963/0000899243-18-019963-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019964/0000899243-18-019964-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019965/0000899243-18-019965-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019967/0000899243-18-019967-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019968/0000899243-18-019968-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019972/0000899243-18-019972-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019974/0000899243-18-019974-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019975/0000899243-18-019975-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019978/0000899243-18-019978-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019979/0000899243-18-019979-index.htm
2018-07-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318020264/0000899243-18-020264-index.htm
2019-02-125Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924319003318/0000899243-19-003318-index.htm
2019-02-125Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924319003326/0000899243-19-003326-index.htm
2020-04-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924320010940/0000899243-20-010940-index.htm
2018-07-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000094787118000610/0000947871-18-000610-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000101297518000919/0001012975-18-000919-index.htm
2018-07-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000101297518000925/0001012975-18-000925-index.htm
2018-08-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000101297518001046/0001012975-18-001046-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465918045567/0001104659-18-045567-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465918045579/0001104659-18-045579-index.htm
2018-07-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465918046292/0001104659-18-046292-index.htm
2018-07-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465918046330/0001104659-18-046330-index.htm
2018-07-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000110465918048071/0001104659-18-048071-index.htm
2019-01-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465919003219/0001104659-19-003219-index.htm
2019-02-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465919006113/0001104659-19-006113-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000110465919008632/0001104659-19-008632-index.htm
2019-02-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465919010154/0001104659-19-010154-index.htm
2019-03-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465919016338/0001104659-19-016338-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465919037468/0001104659-19-037468-index.htm
2020-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000110465920011470/0001104659-20-011470-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000110465920021136/0001104659-20-021136-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000114420419008307/0001144204-19-008307-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000117266120000650/0001172661-20-000650-index.htm
2018-07-128-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1658247/000119312518216421/0001193125-18-216421-index.htm
2018-07-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1658247/000119312518217820/0001193125-18-217820-index.htm
2018-07-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1658247/000119312518217824/0001193125-18-217824-index.htm
2018-07-17S-1MEFRegistration adding securities to prior Form S-1 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1658247/000119312518219860/0001193125-18-219860-index.htm
2018-07-18424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1658247/000119312518220701/0001193125-18-220701-index.htm
2018-07-18S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1658247/000119312518220704/0001193125-18-220704-index.htm
2018-07-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000119312518222517/0001193125-18-222517-index.htm
2018-07-30SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1658247/000119312518231543/0001193125-18-231543-index.htm
2018-08-28SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1658247/000119312518259557/0001193125-18-259557-index.htm
2018-08-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000119312518263610/0001193125-18-263610-index.htm
2018-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000119312518289506/0001193125-18-289506-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000119312518325476/0001193125-18-325476-index.htm
2019-08-13S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1658247/000119312519220012/0001193125-19-220012-index.htm
2019-08-19S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1658247/000119312519224488/0001193125-19-224488-index.htm
2019-08-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1658247/000119312519224495/0001193125-19-224495-index.htm
2019-08-27CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1658247/000119312519230761/0001193125-19-230761-index.htm
2020-04-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000119312520099551/0001193125-20-099551-index.htm
2020-04-14424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1658247/000119312520107151/0001193125-20-107151-index.htm
2020-04-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000119312520107156/0001193125-20-107156-index.htm
2020-04-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000119312520108092/0001193125-20-108092-index.htm
2020-04-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1658247/000119312520108096/0001193125-20-108096-index.htm
2020-04-20SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1658247/000119312520111625/0001193125-20-111625-index.htm
2019-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119018982/0001209191-19-018982-index.htm
2019-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119018983/0001209191-19-018983-index.htm
2019-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119018984/0001209191-19-018984-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119038894/0001209191-19-038894-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119038896/0001209191-19-038896-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119038897/0001209191-19-038897-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119038902/0001209191-19-038902-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119038905/0001209191-19-038905-index.htm
2019-07-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119042285/0001209191-19-042285-index.htm
2019-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119042286/0001209191-19-042286-index.htm
2019-08-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119045039/0001209191-19-045039-index.htm
2019-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119061184/0001209191-19-061184-index.htm
2020-02-115Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120008269/0001209191-20-008269-index.htm
2020-02-115Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120008272/0001209191-20-008272-index.htm
2020-02-115Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120008280/0001209191-20-008280-index.htm
2020-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120012974/0001209191-20-012974-index.htm
2020-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120012987/0001209191-20-012987-index.htm
2020-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120012997/0001209191-20-012997-index.htm
2020-03-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120021372/0001209191-20-021372-index.htm
2020-04-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120026196/0001209191-20-026196-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120038153/0001209191-20-038153-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120038161/0001209191-20-038161-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120038166/0001209191-20-038166-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120038172/0001209191-20-038172-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120038179/0001209191-20-038179-index.htm
2020-07-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120042897/0001209191-20-042897-index.htm
2020-09-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120049508/0001209191-20-049508-index.htm
2020-09-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120049518/0001209191-20-049518-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2020-02-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020002831/0001213900-20-002831-index.htm
2020-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020003326/0001213900-20-003326-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020003601/0001213900-20-003601-index.htm
2020-03-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020006030/0001213900-20-006030-index.htm
2020-04-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020008792/0001213900-20-008792-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020009500/0001213900-20-009500-index.htm
2020-06-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020014709/0001213900-20-014709-index.htm
2018-07-12CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1658247/000135445718000250/0001354457-18-000250-index.htm
2018-08-3010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459018022504/0001564590-18-022504-index.htm
2018-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459018029304/0001564590-18-029304-index.htm
2019-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459019007555/0001564590-19-007555-index.htm
2019-03-1310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1658247/000156459019007561/0001564590-19-007561-index.htm
2019-04-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459019011511/0001564590-19-011511-index.htm
2019-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1658247/000156459019013719/0001564590-19-013719-index.htm
2019-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1658247/000156459019013723/0001564590-19-013723-index.htm
2019-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459019018827/0001564590-19-018827-index.htm
2019-05-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459019018831/0001564590-19-018831-index.htm
2019-06-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459019023431/0001564590-19-023431-index.htm
2019-07-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459019025016/0001564590-19-025016-index.htm
2019-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459019031797/0001564590-19-031797-index.htm
2019-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459019031801/0001564590-19-031801-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459019042893/0001564590-19-042893-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459019042900/0001564590-19-042900-index.htm
2020-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000156459020004205/0001564590-20-004205-index.htm
2020-03-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020009362/0001564590-20-009362-index.htm
2020-03-0910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1658247/000156459020009365/0001564590-20-009365-index.htm
2020-04-28DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1658247/000156459020019202/0001564590-20-019202-index.htm
2020-04-28DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1658247/000156459020019210/0001564590-20-019210-index.htm
2020-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020023260/0001564590-20-023260-index.htm
2020-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459020023265/0001564590-20-023265-index.htm
2020-06-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020030117/0001564590-20-030117-index.htm
2020-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020038067/0001564590-20-038067-index.htm
2020-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459020038069/0001564590-20-038069-index.htm
2020-09-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020042431/0001564590-20-042431-index.htm
2020-09-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020044046/0001564590-20-044046-index.htm
2020-10-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020047499/0001564590-20-047499-index.htm
2020-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020051684/0001564590-20-051684-index.htm
2020-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459020051686/0001564590-20-051686-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000161577418006600/0001615774-18-006600-index.htm
2018-07-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000161577418006729/0001615774-18-006729-index.htm
2018-07-26SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000161577418006903/0001615774-18-006903-index.htm
2019-03-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000161577419004434/0001615774-19-004434-index.htm
2018-07-17EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1658247/999999999518001811/9999999995-18-001811-index.htm
2019-08-29EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1658247/999999999519002011/9999999995-19-002011-index.htm

Crinetics Pharmaceuticals, Inc (CRNX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Crinetics Pharmaceuticals, Inc (CRNX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 450%
Institutional Ownership: 9514%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-03-185AM Ventures IV, L.P.10% Share HolderSell6,194.0024.25150,208.84104,489.00https://www.sec.gov/Archives/edgar/data/1658247/000110465919016338/0001104659-19-016338-index.htm
2019-08-05Richard Scott StruthersPresident & CEOBuy10,000.001.9119,100.001,225,805.00https://www.sec.gov/Archives/edgar/data/1658247/000120919119045039/0001209191-19-045039-index.htm
2019-12-16Matthew K FustDirectorSell3,500.0022.5078,750.0012,536.00https://www.sec.gov/Archives/edgar/data/1658247/000120919119061184/0001209191-19-061184-index.htm
2019-01-225AM Ventures IV, L.P.10% Share HolderSell10,486.0021.88229,381.25129,483.00https://www.sec.gov/Archives/edgar/data/1658247/000110465919003219/0001104659-19-003219-index.htm
2018-07-205AM Ventures IV, L.P.10% Share HolderBuy4,600.0017.0078,200.00139,969.00https://www.sec.gov/Archives/edgar/data/1658247/000110465918046330/0001104659-18-046330-index.htm
2018-07-20Vivo Capital VIII, LLC10% Share HolderBuy141,177.0017.002,400,009.00141,177.00https://www.sec.gov/Archives/edgar/data/1658247/000161577418006729/0001615774-18-006729-index.htm
2019-12-16Matthew K FustDirectorBuy3,500.001.916,685.0016,036.00https://www.sec.gov/Archives/edgar/data/1658247/000120919119061184/0001209191-19-061184-index.htm
2020-03-09Vivo Capital VIII, LLC10% Share HolderSell133.0019.502,593.50168,165.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020006030/0001213900-20-006030-index.htm
2020-02-10Vivo Capital VIII, LLC10% Share HolderSell5,904.0021.40126,345.60168,298.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020003326/0001213900-20-003326-index.htm
2020-02-07Vivo Capital VIII, LLC10% Share HolderSell4,614.0022.00101,508.00174,202.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020003326/0001213900-20-003326-index.htm
2020-02-04Vivo Capital VIII, LLC10% Share HolderSell10,519.0022.80239,833.20178,816.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002831/0001213900-20-002831-index.htm
2020-01-31Vivo Capital VIII, LLC10% Share HolderSell4,220.0021.7091,574.00189,335.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2020-01-30Vivo Capital VIII, LLC10% Share HolderSell5,940.0022.10131,274.00193,555.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2020-01-29Vivo Capital VIII, LLC10% Share HolderSell10,878.0022.20241,491.60199,495.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2018-07-20Alan Seth KrasnerChief Medical OfficerBuy2,000.0017.0034,000.002,000.00https://www.sec.gov/Archives/edgar/data/1658247/000089924318020264/0000899243-18-020264-index.htm
2019-03-20Vivo Capital VIII, LLC10% Share HolderSell83,984.0022.251,868,644.00210,373.00https://www.sec.gov/Archives/edgar/data/1658247/000161577419004434/0001615774-19-004434-index.htm
2020-04-17Vivo Capital VIII, LLC10% Share HolderSell74,333.0015.401,144,728.202,162,587.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020009500/0001213900-20-009500-index.htm
2020-04-16Vivo Capital VIII, LLC10% Share HolderSell26,527.0015.20403,210.402,236,920.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020009500/0001213900-20-009500-index.htm
2020-04-15Vivo Capital VIII, LLC10% Share HolderSell189,625.0015.502,939,187.502,263,447.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020009500/0001213900-20-009500-index.htm
2019-06-215AM Ventures IV, L.P.InsiderSell240,000.0022.205,328,000.002,267,797.00https://www.sec.gov/Archives/edgar/data/1658247/000110465919037468/0001104659-19-037468-index.htm
2018-07-20PERCEPTIVE ADVISORS LLCDirectorBuy400,000.0017.006,800,000.002,280,305.00https://www.sec.gov/Archives/edgar/data/1658247/000101297518000925/0001012975-18-000925-index.htm
2020-04-07Vivo Capital VIII, LLC10% Share HolderSell5,373.0014.2076,296.602,453,072.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020008792/0001213900-20-008792-index.htm
2020-04-03Vivo Capital VIII, LLC10% Share HolderSell263,600.0013.803,637,680.002,458,445.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020008792/0001213900-20-008792-index.htm
2019-03-185AM Ventures IV, L.P.10% Share HolderSell148,645.0024.253,604,745.302,507,797.00https://www.sec.gov/Archives/edgar/data/1658247/000110465919016338/0001104659-19-016338-index.htm
2020-03-09Vivo Capital VIII, LLC10% Share HolderSell347.0019.506,766.502,722,045.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020006030/0001213900-20-006030-index.htm
2020-02-10Vivo Capital VIII, LLC10% Share HolderSell1,451.0021.4031,051.402,722,392.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020003326/0001213900-20-003326-index.htm
2020-02-07Vivo Capital VIII, LLC10% Share HolderSell1,134.0022.0024,948.002,723,843.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020003326/0001213900-20-003326-index.htm
2020-02-04Vivo Capital VIII, LLC10% Share HolderSell2,584.0022.8058,915.202,724,977.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002831/0001213900-20-002831-index.htm
2020-01-31Vivo Capital VIII, LLC10% Share HolderSell1,037.0021.7022,502.902,727,561.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2020-01-30Vivo Capital VIII, LLC10% Share HolderSell1,459.0022.1032,243.902,728,598.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2020-01-29Vivo Capital VIII, LLC10% Share HolderSell2,673.0022.2059,340.602,730,057.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2019-03-20Vivo Capital VIII, LLC10% Share HolderSell292,609.0022.256,510,550.252,732,730.00https://www.sec.gov/Archives/edgar/data/1658247/000161577419004434/0001615774-19-004434-index.htm
2018-07-20Vivo Capital VIII, LLC10% Share HolderBuy153,180.0020.733,175,421.40294,357.00https://www.sec.gov/Archives/edgar/data/1658247/000161577418006729/0001615774-18-006729-index.htm
2020-04-17Vivo Capital VIII, LLC10% Share HolderSell10,265.0015.40158,081.00298,625.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020009500/0001213900-20-009500-index.htm
2018-07-20Vivo Capital VIII, LLC10% Share HolderBuy51,686.0017.00878,662.003,025,339.00https://www.sec.gov/Archives/edgar/data/1658247/000161577418006729/0001615774-18-006729-index.htm
2020-04-16Vivo Capital VIII, LLC10% Share HolderSell3,663.0015.2055,677.60308,890.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020009500/0001213900-20-009500-index.htm
2019-01-225AM Ventures IV, L.P.10% Share HolderSell251,667.0021.885,505,215.633,107,642.00https://www.sec.gov/Archives/edgar/data/1658247/000110465919003219/0001104659-19-003219-index.htm
2020-04-15Vivo Capital VIII, LLC10% Share HolderSell26,185.0015.50405,867.50312,553.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020009500/0001213900-20-009500-index.htm
2018-07-205AM Ventures IV, L.P.10% Share HolderBuy110,400.0017.001,876,800.003,359,309.00https://www.sec.gov/Archives/edgar/data/1658247/000110465918046330/0001104659-18-046330-index.htm
2020-04-07Vivo Capital VIII, LLC10% Share HolderSell742.0014.2010,536.40338,738.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020008792/0001213900-20-008792-index.htm
2020-04-03Vivo Capital VIII, LLC10% Share HolderSell36,400.0013.80502,320.00339,480.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020008792/0001213900-20-008792-index.htm
2020-04-17PERCEPTIVE ADVISORS LLC10% Share HolderBuy1,071,428.0014.0014,999,992.003,659,381.00https://www.sec.gov/Archives/edgar/data/1658247/000089924320010940/0000899243-20-010940-index.htm
2020-03-09Vivo Capital VIII, LLC10% Share HolderSell48.0019.50936.00375,880.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020006030/0001213900-20-006030-index.htm
2020-02-10Vivo Capital VIII, LLC10% Share HolderSell200.0021.404,280.00375,928.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020003326/0001213900-20-003326-index.htm
2020-02-07Vivo Capital VIII, LLC10% Share HolderSell157.0022.003,454.00376,128.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020003326/0001213900-20-003326-index.htm
2020-02-04Vivo Capital VIII, LLC10% Share HolderSell357.0022.808,139.60376,285.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002831/0001213900-20-002831-index.htm
2020-01-31Vivo Capital VIII, LLC10% Share HolderSell143.0021.703,103.10376,642.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2020-01-30Vivo Capital VIII, LLC10% Share HolderSell201.0022.104,442.10376,785.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2020-01-29Vivo Capital VIII, LLC10% Share HolderSell369.0022.208,191.80376,986.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2019-03-20Vivo Capital VIII, LLC10% Share HolderSell40,407.0022.25899,055.75377,355.00https://www.sec.gov/Archives/edgar/data/1658247/000161577419004434/0001615774-19-004434-index.htm
2018-07-20Vivo Capital VIII, LLC10% Share HolderBuy7,137.0017.00121,329.00417,762.00https://www.sec.gov/Archives/edgar/data/1658247/000161577418006729/0001615774-18-006729-index.htm
2020-07-16Richard Scott StruthersPresident & CEOSell17,500.0014.46253,107.75890,805.00https://www.sec.gov/Archives/edgar/data/1658247/000120919120042897/0001209191-20-042897-index.htm
2020-07-15Richard Scott StruthersPresident & CEOSell17,500.0015.30267,722.00908,305.00https://www.sec.gov/Archives/edgar/data/1658247/000120919120042897/0001209191-20-042897-index.htm
2019-06-215AM Ventures IV, L.P.InsiderSell10,000.0022.20222,000.0094,489.00https://www.sec.gov/Archives/edgar/data/1658247/000110465919037468/0001104659-19-037468-index.htm
2020-04-28WENDALL WIERENGADirectorBuy25,329.000.7318,490.1799,846.00https://www.sec.gov/Archives/edgar/data/1658247/000120919120026196/0001209191-20-026196-index.htm